MLS on the verge of breaking above that 31p high of April 2002. This was the item that triggered the current breakout last week:

LONDON (AFX) - Medical Solutions PLC, the cancer and pathology services
group, said The Doctors Laboratory, the leading provider of private cervical
screening in the UK, has stated that they are adopting Medical Solutions'
SurePath for their LBC screening.
The SurePath system will be supplied by Medical Solutions in the UK under
licence from TriPath Imaging Inc.
Medical Solutions chief executive Charles Green said the group now awaits
the NICE (the National Institute of Clinical Excellence) report issuing their
final guidance to the NHS, after their preliminary report recommended the use of
liquid based cytology within the NHS. This report is expected in September.
newsdesk@afxnews.com
slm/

See impressive bb comment here since then and on various BBs.

Interims due mid-Sept.
Ahead of a long weekend there might yet be some profit-taking, but with results and statements to come within the next 2-3 weeks I would guess most who are planning to do so will reduce rather than exit, and the effect will be perhaps be outweighed by new buyers waking up to what's happening.

MLS don't have the field to themselves with the nhs - there are still other contenders in the running. But it's looking hopeful in my opinion.

Company website

External Shareholders at 21 Aug 03:
89.15m 2p Ords - Edinburgh Fund Mgrs PLC 6.32%, INVESCO Asset Mgmt Ltd 5.78%, Prudential PLC 5.61%, Cantor Fitzgerald Europe 5.34%, Texas Group PLC 4.12%, Singer & Friedlander Inv 3.45%, Other Dirs 1.65%.

jzl

Sold half my holding this morning for +50% which was nice.

RNS Number:1624R
Medical Solutions PLC
22 October 2003





October 22, 2003



Medical Solutions announces Department of Health decision on

Liquid Based Cytology





Medical Solutions (LSE: MLS), the cancer diagnostics company, announces that the
Department of Health has today accepted the decision by NICE that a new cervical
screening system - Liquid Based Cytology ("LBC") will replace the current
cervical smear test in England and Wales.



Medical Solutions will supply its SurePath LBC system, which has been used for
the NICE (National Institute of Clinical Excellence) pilot study. The
excellent results the SurePath LBC System obtained in the NICE pilot for both
cancer detection and reduction in inadequate tests has greatly contributed to
the decision by DOH to adopt the NICE guidance on LBC in England and Wales.



The SurePath LBC system is more effective than conventional smear tests in
picking up likely cancer cases and US studies have demonstrated a 64.4%
improvement over conventional methods in the detection of high grade
abnormalities. The system introduced by SurePath is automated thereby reducing
any operator errors and increasing the efficiency of the new LBC test. Early
detection of such abnormalities greatly increases the chances of effective
treatment.



LBC is also a significant step towards the introduction of even more powerful
detection tools in the future including automatic imaging and molecular markers.
The SurePath LBC system already has some of these systems approved in the US and
trials are underway in the UK.



Charles Green CEO of Medical Solutions said



"We are delighted by the Department of Health's adoption of LBC in England and
Wales. The Medical Solutions Surepath LBC system is one of only two FDA
approved products and our unique technologies will ensure greatly improved
collection and screening of the four million smears performed every year."



Contact:



Medical Solutions
Charles Green, Chief Executive Officer Tel: +44 (0) 115 973 9010

anymoe good news? look like this share worth to hold from now on....

GREAT NEWS FOR YOU/SHAREHOLDERS
Up 8.50 / 17.99 per cent @ 4,736,092 million volume
I forget the www I found it.
................................
More info:
www.moneyextra.com/stocks/LSE/MLS---------Click company news.

Plenty of favourable press coverage this weekend so far. Some profit-taking was to be expected yesterday at the end of such a positive week, but the share price soaked up those sells with ease.

Analysts and brokers newly alerted to this stock by the nhs and related government statement should be coming up with upgrades soon. Plus the possibility of it becoming a very tasty takeover target now that it looks like taking a fair chunk of that nhs business. Not that it is reliant on the LBC cervical cancer testing work. It has several solid divisions (expect some newsflow from those between now and end of year).

Sonic (Australian Top-100 company) has an active connection with MLS on several fronts and is considered by many to be a likely bidder at some stage.

jzl

Some more on Sonic - lifted from an excellent piece by S-H-B on another BB:

..Sonic is the largest medical diagnostics Company in Australasia and New Zealand, providing quality Pathology and radiology services in the community.

...has made rapid progress and turnover is now almost 1billion AUS dollars.

Sonic Stategy:
Capture synergies with Sonic pathology
Build relationships with independent healthcare entities
Acquisitions
UK pathology opportunities
European pathology

Sonic Statement:
The group’s UK operation, TDL, continues to perform strongly, with significant growth in both revenue and EBITA. Recent developments in the UK include the acquisition of the Omnilabs pathology group in July 2003 and the announcement of a strategic joint venture with the University College London Hospital (UCLH), one of the UK’s most prestigious teaching hospitals. TDL (including the merged Omnilabs operation), is expected to move into a new, state-of-the-art laboratory facility in December 2003 and will partner with UCLH to form a high-volume automated laboratory in the new facility for the routine pathology testing of both entities.

Dr Goldschmidt said that the UCLH joint venture represented an important milestone in Sonic’s history. “We are privileged to work with UCLH and we anticipate that the relationship will bring benefits to both groups at many levels. The TDL/UCLH joint venture will create the platform for growth in both the public and private pathology markets in the UK"


As above, Sonic are very very keen to gain a major foothold in the NHS, and be part of the NHS Pathology modernisation plan this has been achieved with having contracts with the NHS through TDL, and now having very close ties with MLS who are firmly established throughout the NHS, this puts Sonic now in the position as a 'stalking horse' waiting for the opportune moment to make their move on MLS.

Karol Sikora is an advisor for Astra Zeneca and does work for HCA a large US Healthcare company, But Sonic are purely a diagnostics company who have a foothold in the UK market and with Medicals business operations would be an ideal synergistic fit for Sonic.

Detailed info about Sonic and Company stategies can be found on this link
http://www.sonichealthcare.com/sonic/internet/html_corporate/index.html

2004 saw Medical Solution go from Greatness to Weakness, yet here there are no comments - - -

This stock has got to be a one way bet, it'll go back up as fast as it fell as soon as some news is out. Any thoughts on this one's future

20 times as many buys as sells today, and previous days. Something big is coming soon

snaylor

Clearly, the placing has gone well. My information is that the new board members have been well received. The city has clearly backed them in seeing off the hostile bid. Thus it is seen that the company should recover. I doubt whether there has been time for any trading improvement. Rather, the fall was overdone.

Eric

Fascinated at the lack of comment on this bb. Positive news out to day with Surepath sales. Successful fundraising behind them. Strong new board members on board. Focussing on getting the finances in order. What is more: Evil Knievel has a LONG position in MLS. Anyone with inside view of the market?

Eric

Another post to repeat the question of the last one to keep it on top page. I will go on doing this until I get an answer! Can anyone tell me what this company is worth?

Eric

Not me;- but I did buy-in a lot higher in the days when they were about to gain NHS money, which I understand has been their downfall.
/
When a co really disapoints it takes a lot of positive news (over a sustained time) to convince folk that the company is worthwhile. I haven't subscribed recently as it was too close to the market price IMHO. The drift down more-or-less confirms this. Maybe a new strategy is in order, but the sp will not react until it shows some results.
Keep asking the questions, EWRobson - someone must know.

Thanks, hangon. I think you are right re the need for sustained good news. There are many AIM companies way down from their best and below placing prices. There doesn't appear to be much hot money there for breaking positive stories either. You keep wondering whether companies like MLS, YOO and CYH can drift lower and they do, because of lack of buyers.

Would also appreciate others views on this stock and think you are both correct re the need for continual good news.

From my understanding MLS is not an Aim stock.

Thanks for trying to keep this on the top page.

Sorry, the same old chap and not another! Just been looking at the Hemscott figures and the updated broker forecasts. Charles Stanley, house broker, have reduced from Buy to Hold. What is more, or less, they are not forecasting profits in the next two financial years. So I doubt if tis a buy this time of the summer recess - there's so much more positive around which is not moving. Hold might be OK because price might just bobble along the bottom for a while.

Eric

8 June 2006

Medical Solutions plc

("Medical Solutions" or "the Group")

Annual General Meeting

Sir Gareth Roberts, Chairman of Medical Solutions plc will be making the
following statement at the 2006 Annual General Meeting today:

"Following the significant improvement in the Group's financial and operating
performance during 2005, I am pleased to report that excellent progress has
been made during the early part of 2006.

Trading update

We stated in our 2005 Annual Report that we had targeted sales growth rates of
around 20-25% for the year ending 31 December 2006 and I am delighted to report
that, over the early part of the year, this is a target that we have exceeded.
Our operating costs remain under control and our cash position has been well
managed.

This is good news for the future, probaly why someone bought significant 1m recently.

A good post from AFN, which may be linked to EK and talk about Cancer treatments etc.. that might be throwing lots of lots of money the way of MLS..


Rex Taurus - 9 Jun'06 - 09:47


From yesterday's AGM statement:


In the UK Diagnostic Pathology business, progress during the early part of the
year has been excellent following the continued high demand experienced for our
service offerings, including the Her 2 test, designed to establish whether or
not a patient suffering with breast cancer will respond to the drug
HerceptinTM.



Today's News:

http://icwales.icnetwork.co.uk/0100news/0200wales/tm_objectid=17201787&method=full&siteid=50082&headline=-thousands-of-lives-saved--as-herceptin-approved-for-nhs-name_page.html

'Thousands of lives saved' as Herceptin approved

Notice of Results

RNS Number:1211I
Medical Solutions PLC
25 August 2006


Medical Solutions plc

Notice of Interim Results

Medical Solutions plc, the provider of pathology and cytology products and
services to the healthcare and pharmaceuticals sector, will announce interim
results for the six months ended 30 June 2006 on Thursday 31 August 2006.

-Ends-

For further information:

Medical Solutions
Neil Johnston 0115 973 9010

Bell Pottinger
Geoff Callow/Chris Hamilton 020 7861 3232




This information is provided by RNS
The company news service from the London Stock Exchange